Scarica l'app Stockscreener
60.06
2.17%
-1.285
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché DXCM Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$61.35
Aprire:
$61.61
Volume 24 ore:
1.68M
Relative Volume:
0.37
Capitalizzazione di mercato:
$23.18B
Reddito:
$4.66B
Utile/perdita netta:
$836.30M
Rapporto P/E:
28.70
EPS:
2.093
Flusso di cassa netto:
$1.08B
1 W Prestazione:
-2.26%
1M Prestazione:
-3.53%
6M Prestazione:
-1.89%
1 anno Prestazione:
-26.46%
Intervallo 1D:
$59.16
$61.63
Intervallo di 1 settimana:
$56.72
$62.85
Portata 52W:
$54.11
$89.98
Dexcom Inc Stock (DXCM) Company Profile
Nome
Dexcom Inc
Settore
Industria
Telefono
(858) 200-0200
Indirizzo
6340 SEQUENCE DRIVE, SAN DIEGO, CA
Compare DXCM vs ABT, SYK, MDT, BSX, EW
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
DXCM
Dexcom Inc
|
60.07 | 23.67B | 4.66B | 836.30M | 1.08B | 2.093 |
ABT
Abbott Laboratories
|
88.06 | 155.82B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
291.30 | 112.88B | 25.27B | 3.34B | 4.57B | 8.6358 |
MDT
Medtronic Plc
|
78.94 | 102.71B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
57.06 | 83.97B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
83.90 | 48.42B | 6.30B | 1.07B | 1.34B | 1.8406 |
Dexcom Inc Stock (DXCM) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-24 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2026-01-12 | Downgrade | Barclays | Equal Weight → Underweight |
| 2025-12-02 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2025-11-25 | Iniziato | Evercore ISI | In-line |
| 2025-10-21 | Ripresa | Stifel | Buy |
| 2025-09-08 | Downgrade | Oppenheimer | Outperform → Perform |
| 2025-08-21 | Iniziato | Argus | Buy |
| 2025-06-16 | Iniziato | Truist | Buy |
| 2025-05-30 | Iniziato | Goldman | Buy |
| 2025-04-10 | Iniziato | Mizuho | Outperform |
| 2025-02-03 | Aggiornamento | Redburn Atlantic | Neutral → Buy |
| 2025-01-16 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2024-07-26 | Downgrade | JP Morgan | Overweight → Neutral |
| 2024-07-26 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2024-05-30 | Iniziato | Redburn Atlantic | Neutral |
| 2024-03-12 | Iniziato | RBC Capital Mkts | Outperform |
| 2023-05-30 | Ripresa | Morgan Stanley | Equal-Weight |
| 2023-04-17 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2023-03-29 | Iniziato | UBS | Buy |
| 2023-01-26 | Iniziato | Wolfe Research | Outperform |
| 2022-10-18 | Iniziato | Barclays | Equal Weight |
| 2022-10-12 | Iniziato | Jefferies | Buy |
| 2022-07-15 | Iniziato | Bernstein | Outperform |
| 2022-03-02 | Ripresa | BofA Securities | Buy |
| 2022-02-03 | Aggiornamento | BTIG Research | Neutral → Buy |
| 2022-01-19 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2022-01-07 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2021-10-18 | Downgrade | Guggenheim | Buy → Neutral |
| 2021-07-21 | Ripresa | Cowen | Outperform |
| 2021-05-28 | Aggiornamento | Wells Fargo | Underweight → Equal Weight |
| 2021-05-25 | Iniziato | Barclays | Overweight |
| 2021-04-15 | Iniziato | Atlantic Equities | Overweight |
| 2021-01-06 | Aggiornamento | UBS | Neutral → Buy |
| 2020-10-02 | Downgrade | Wells Fargo | Equal Weight → Underweight |
| 2020-05-27 | Reiterato | Piper Sandler | Overweight |
| 2020-05-14 | Iniziato | Wells Fargo | Equal Weight |
| 2020-03-05 | Iniziato | Citigroup | Buy |
| 2019-11-07 | Reiterato | Canaccord Genuity | Buy |
| 2019-11-07 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2019-10-23 | Iniziato | Stifel | Buy |
| 2018-11-28 | Iniziato | UBS | Neutral |
| 2018-10-19 | Aggiornamento | Goldman | Sell → Neutral |
| 2018-09-12 | Aggiornamento | Northland Capital | Under Perform → Market Perform |
| 2018-08-02 | Reiterato | Canaccord Genuity | Buy |
| 2018-07-02 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2018-06-08 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2018-05-11 | Iniziato | BofA/Merrill | Buy |
| 2018-05-03 | Reiterato | Canaccord Genuity | Buy |
| 2018-04-04 | Iniziato | Goldman | Sell |
| 2018-04-04 | Iniziato | Guggenheim | Neutral |
| 2018-03-23 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2018-01-04 | Downgrade | Northland Capital | Market Perform → Under Perform |
| 2017-09-28 | Reiterato | Wedbush | Outperform |
Mostra tutto
Dexcom Inc Borsa (DXCM) Ultime notizie
DexCom Stock Up on Q1 Earnings & Revenues Beat, Margins Rise - MSN
Canaccord Genuity Adjusts Price Target on DexCom to $100 From $95, Maintains Buy Rating - Moomoo
Dexcom, Inc. Q1 2026 Financial Results: Strong Revenue, Earnings, and Forward-Looking Statements - Minichart
DexCom Inc. stock outperforms competitors on strong trading day - MarketWatch
DexCom Faces Potential Headwinds in 2026, but Expanding Reimbursement Offers Long-Term Prospects - Morningstar
DexCom Medicare Coverage NCD Remains Biggest 2026 Catalyst, RBC Says - marketscreener.com
JPMorgan Adjusts DexCom Price Target to $65 From $75 - marketscreener.com
DexCom, Inc. 2026 Q1ResultsEarnings Call Presentation (NASDAQ:DXCM) 2026-05-01 - Seeking Alpha
DexCom, Inc. (NASDAQ:DXCM) Q1 2026 Earnings Call Transcript - Insider Monkey
Dexcom reports 15% YoY revenue uptick in Q1 yet maintains prior FY26 outlook - Yahoo Finance
DexCom Inc (NASDAQ:DXCM): A GARP Stock with Affordable Growth and Strong Fundamentals - ChartMill
Barclays Adjusts Price Target on DexCom to $67 From $72, Maintains Underweight Rating - marketscreener.com
Leerink Partners Adjusts Price Target on DexCom to $80 From $95, Maintains Outperform Rating - marketscreener.com
Bernstein Adjusts Price Target on DexCom to $77 From $83, Maintains Outperform Rating - marketscreener.com
Bernstein SocGen lowers DexCom stock price target on valuation By Investing.com - Investing.com Canada
Raymond James Adjusts Price Target on DexCom to $81 From $83, Maintains Strong Buy Rating - marketscreener.com
Goldman Sachs Adjusts Price Target on DexCom to $80 From $82, Maintains Buy Rating - marketscreener.com
TD Cowen Adjusts Price Target on DexCom to $75 From $84, Maintains Buy Rating - marketscreener.com
Citigroup Adjusts Price Target on DexCom to $79 From $84, Maintains Buy Rating - marketscreener.com
Mizuho cuts DexCom stock price target to $75 on valuation reset - Investing.com
HB Wealth Management LLC Cuts Stake in DexCom, Inc. $DXCM - MarketBeat
BTIG Remains Bullish on DexCom, Inc. (DXCM) - Insider Monkey
DXCM Stock Price, Quote & Chart | DEXCOM INC (NASDAQ:DXCM) - ChartMill
DexCom Inc (DXCM) Q1 2026 Earnings Call Highlights: Strong Reven - GuruFocus
DexCom Inc (DXCM) Q1 2026 Earnings Call Highlights: Strong Revenue Growth and Strategic Market Expansions - GuruFocus
DexCom Inc (DXCM) Stock Price, Trades & News - GuruFocus
DexCom Q1 2026 slides: margin expansion accelerates, guidance raised By Investing.com - Investing.com South Africa
MSN Money - MSN
DexCom (DXCM) Reports Strong Q1 2026 Revenue Growth Driven by Pr - GuruFocus
Is It Too Late to Buy DexCom Inc (DXCM) After 3.5% Rally? GF Value Says Undervalued - GuruFocus
Is DexCom (DXCM) 45.7% Undervalued After Q1 2026 Earnings Beat? - GuruFocus
Is It Too Late to Buy DexCom Inc (DXCM) After 3.5% Rally? GF Val - GuruFocus
DexCom (DXCM) Q1 2026 Earnings Transcript - The Motley Fool
DexCom Q1 Earnings Call Highlights - Yahoo Finance
Earnings call transcript: DexCom beats Q1 2026 forecasts, stock rises - Investing.com
Transcript : DexCom, Inc., Q1 2026 Earnings Call, Apr 30, 2026 - marketscreener.com
DexCom Q1 2026 Earnings Call Transcript - Benzinga
DexCom, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
DexCom (DXCM) Q1 Earnings and Revenues Top Estimates - Yahoo Finance Singapore
Dexcom reaffirms full-year forecast after topping quarterly estimates - marketscreener.com
Dexcom shares fell as it reaffirms full-year outlook By Investing.com - Investing.com Canada
DexCom (NASDAQ:DXCM) Beats Q1 Earnings Forecasts, But Guidance and Revenue Miss Fuel After-Hours Drop - ChartMill
Dexcom falls over 5% despite better-than-expected Q1 print, as revenue guidance disappoints - Investing.com India
Q1 2026 Dexcom Inc Earnings Call Transcript - GuruFocus
DexCom Q1 Adjusted Earnings, Revenue Rise - marketscreener.com
DexCom (NASDAQ:DXCM) Exceeds Q1 CY2026 Expectations But Stock Drops - Yahoo Finance
Earnings Flash (DXCM) DexCom, Inc. Reports Q1 Revenue $1.19B, vs. FactSet Est of $1.17B - marketscreener.com
Earnings Flash (DXCM) DexCom, Inc. Posts Q1 Adjusted EPS $0.56 per Share, vs. FactSet Est of $0.47 - marketscreener.com
DexCom: Q1 Earnings Snapshot - marketscreener.com
[8-K] DEXCOM INC Reports Material Event - Stock Titan
DexCom, Inc. Reiterates Earnings Guidance for the Fiscal Year 2026 - marketscreener.com
Dexcom Inc Azioni (DXCM) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.04%
0.86%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):